{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:11:38Z","timestamp":1741313498361,"version":"3.38.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02702"],"award-info":[{"award-number":["21H02702"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005611","name":"University of Fukui","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005611","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Only a few human ovarian endometrioid carcinoma cell lines are currently available, partly due to the difficulty of establishing cell lines from low-grade cancers. Here, using a cell immortalization strategy consisting of i) inactivation of the p16<jats:sup>INK4a<\/jats:sup>-pRb pathway by constitutive expression of mutant cyclin-dependent kinase 4 (R24C) (CDK4<jats:sup>R24C<\/jats:sup>) and cyclin D1, and ii) acquisition of telomerase reverse transcriptase (TERT) activity, we established a human ovarian endometrioid carcinoma cell line from a 46-year-old Japanese woman. That line, designated JFE-21, has proliferated continuously for over 6\u00a0months with a doubling time of\u2009~\u200955\u00a0h. JFE-21 cells exhibit polygonal shapes and proliferate without contact inhibition to form a monolayer in a jigsaw puzzle-like arrangement. Ultrastructurally, JFE-21 cells exhibit well-developed rough endoplasmic reticulum, mitochondria and lysosomes in the cytoplasm, with cells contacting each other via desmosomes. G-band karyotype analysis indicated that cells had a near-tetraploid karyotype. Immunofluorescence staining revealed that the expression profile of a series of ovarian carcinoma markers in JFE-21 cells was consistent with ovarian endometrioid carcinoma. Moreover, Sanger sequencing of DNA polymerase \u03b5 (<jats:italic>POLE<\/jats:italic>) gene and immunohistochemical analysis of mismatch repair (MMR) proteins revealed that JFE-21 cells were classified as the no specific molecular profile (NSMP) subtype. In addition, JFE-21 cells were sensitive to paclitaxel and carboplatin administered to the donor as therapy. These findings indicate that constitutive expression of CDK4<jats:sup>R24C<\/jats:sup>, cyclin D1 and TERT genes may be an option to establish cell lines from low-grade cancers, including ovarian endometrioid carcinoma.<\/jats:p>","DOI":"10.1007\/s13577-025-01176-0","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T09:50:19Z","timestamp":1738144219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Establishment of a human ovarian endometrioid carcinoma cell line by constitutive expression of cyclin-dependent kinase 4, cyclin D1 and telomerase reverse transcriptase"],"prefix":"10.1007","volume":"38","author":[{"given":"Hitomi","family":"Hoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya O.","family":"Akama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzuko","family":"Moritani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Shigeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mana","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-0801","authenticated-orcid":false,"given":"Motohiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"6","key":"1176_CR1","doi-asserted-by":"publisher","first-page":"S227","DOI":"10.1016\/S0002-9378(97)70379-X","volume":"176","author":"HW Jones Jr","year":"1997","unstructured":"Jones HW Jr. Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line. Am J Obstet Gynecol. 1997;176(6):S227\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"1176_CR2","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1038\/ncomms8419","volume":"6","author":"TA Ince","year":"2015","unstructured":"Ince TA, Sousa AD, Jones MA, et al. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun. 2015;6:7419.","journal-title":"Nat Commun"},{"issue":"2","key":"1176_CR3","first-page":"845","volume":"9","author":"CF Verschraegen","year":"2003","unstructured":"Verschraegen CF, Hu W, Du Y, et al. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003;9(2):845\u201352.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1176_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/0090-8258(84)90217-8","volume":"17","author":"S Uehara","year":"1984","unstructured":"Uehara S, Abe H, Hoshiai H, Yajima A, Suzuki M. Establishment and characterization of ovarian endometrioid carcinoma cell line. Gynecol Oncol. 1984;17(3):314\u201325.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1176_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1290\/1071-2690(2000)036<0357:COFNEO>2.0.CO;2","volume":"36","author":"DM Provencher","year":"2000","unstructured":"Provencher DM, Lounis H, Champoux L, et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim. 2000;36(6):357\u201361.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"3","key":"1176_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1749-0774.2007.00030.x","volume":"20","author":"T Umezu","year":"2007","unstructured":"Umezu T, Kajiyama H, Terauchi M, et al. Establishment of a new cell line of endometrioid carcinoma of the ovary and its chemosensitivity. Hum Cell. 2007;20(3):71\u20136.","journal-title":"Hum Cell"},{"issue":"1","key":"1176_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1006\/gyno.1998.5259","volume":"73","author":"JK Wolf","year":"1999","unstructured":"Wolf JK, Kim TE, Fightmaster D, et al. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol. 1999;73(1):27\u201334.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1176_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/gt.2011.44","volume":"18","author":"K Shiomi","year":"2011","unstructured":"Shiomi K, Kiyono T, Okamura K, et al. CDK4 and cyclin D1 allow human myogenic cells to recapture growth property without compromising differentiation potential. Gene Ther. 2011;18(9):857\u201366.","journal-title":"Gene Ther"},{"issue":"1","key":"1176_CR9","doi-asserted-by":"publisher","first-page":"17503","DOI":"10.1038\/s41598-020-73992-3","volume":"10","author":"M Nishiwaki","year":"2020","unstructured":"Nishiwaki M, Toyoda M, Oishi Y, et al. Immortalization of human hepatocytes from biliary atresia with CDK4R24C, cyclin D1, and TERT for cytochrome P450 induction testing. Sci Rep. 2020;10(1):17503.","journal-title":"Sci Rep"},{"issue":"2","key":"1176_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"10","key":"1176_CR11","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41374-019-0267-0","volume":"99","author":"M Tsutsumiuchi","year":"2019","unstructured":"Tsutsumiuchi M, Hoshino H, Kogami A, et al. Preferential expression of sialyl 6\u2019-sulfo N-acetyllactosamine-capped O-glycans on high endothelial venules in human peripheral lymph nodes. Lab Invest. 2019;99(10):1428\u201341.","journal-title":"Lab Invest"},{"issue":"4","key":"1176_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/nar\/24.4.596","volume":"24","author":"M Jordan","year":"1996","unstructured":"Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 1996;24(4):596\u2013601.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1176_CR13","doi-asserted-by":"publisher","first-page":"e50519","DOI":"10.1371\/journal.pone.0050519","volume":"7","author":"T Sueblinvong","year":"2012","unstructured":"Sueblinvong T, Ghebre R, Iizuka Y, et al. Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS ONE. 2012;7(11):e50519.","journal-title":"PLoS ONE"},{"issue":"5","key":"1176_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1369\/0022155412437613","volume":"60","author":"M Fujiwara","year":"2012","unstructured":"Fujiwara M, Kobayashi M, Hoshino H, et al. Expression of long-form N-acetylglucosamine-6-O-sulfotransferase 1 in human high endothelial venules. J Histochem Cytochem. 2012;60(5):397\u2013407.","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"1176_CR15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s13577-024-01058-x","volume":"37","author":"H Hoshino","year":"2024","unstructured":"Hoshino H, Inoue D, Shinagawa A, et al. Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA. Hum Cell. 2024;37(4):1184\u201393.","journal-title":"Hum Cell"},{"volume-title":"ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020)","year":"2020","key":"1176_CR16","unstructured":"McGowan-Jordan J, Hastings RJ, Moore S, editors. ISCN 2020: An International System for Human Cytogenomic Nomenclature (2020). Basel: Karger; 2020."},{"issue":"7","key":"1176_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1572-0241.2007.01189.x","volume":"102","author":"K Suzawa","year":"2007","unstructured":"Suzawa K, Kobayashi M, Sakai Y, et al. Preferential induction of peripheral lymph node addressin on high endothelial venule-like vessels in the active phase of ulcerative colitis. Am J Gastroenterol. 2007;102(7):1499\u2013509.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1176_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc.2015.12","volume":"16","author":"E Rayner","year":"2016","unstructured":"Rayner E, van Gool IC, Palles C, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat Rev Cancer. 2016;16(2):71\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"1176_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1369\/00221554231199134","volume":"71","author":"A Muramoto","year":"2023","unstructured":"Muramoto A, Inamura S, Hoshino H, Terada N, Kobayashi M. Paradoxical expression of R-10G-reactive antigen in human testicular embryonal carcinoma. J Histochem Cytochem. 2023;71(10):555\u201363.","journal-title":"J Histochem Cytochem"},{"issue":"11","key":"1176_CR20","doi-asserted-by":"publisher","first-page":"496.e1","DOI":"10.1016\/j.urolonc.2015.05.026","volume":"33","author":"M Taga","year":"2015","unstructured":"Taga M, Hoshino H, Low S, et al. A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma. Urol Oncol. 2015;33(11):496.e1-9.","journal-title":"Urol Oncol"},{"issue":"3","key":"1176_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00408-022-00531-4","volume":"200","author":"K Nakashima","year":"2022","unstructured":"Nakashima K, Sakai Y, Hoshino H, et al. Sulfated glycans recognized by S1 monoclonal antibody can serve as a diagnostic marker for malignant pleural mesothelioma. Lung. 2022;200(3):339\u201346.","journal-title":"Lung"},{"issue":"6","key":"1176_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/PGP.0000000000000564","volume":"38","author":"R Woodbeck","year":"2019","unstructured":"Woodbeck R, Kelemen LE, K\u00f6bel M. Ovarian endometrioid carcinoma misdiagnosed as mucinous carcinoma: an underrecognized problem. Int J Gynecol Pathol. 2019;38(6):568\u201375.","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"1176_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/PGP.0000000000000274","volume":"35","author":"M K\u00f6bel","year":"2016","unstructured":"K\u00f6bel M, Rahimi K, Rambau PF, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016;35(5):430\u201341.","journal-title":"Int J Gynecol Pathol"},{"issue":"5","key":"1176_CR24","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/path.5034","volume":"244","author":"J McAlpine","year":"2018","unstructured":"McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244(5):538\u201349.","journal-title":"J Pathol"},{"issue":"20","key":"1176_CR25","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1158\/1078-0432.CCR-20-1268","volume":"26","author":"P Kr\u00e4mer","year":"2020","unstructured":"Kr\u00e4mer P, Talhouk A, Brett MA, et al. Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma. Clin Cancer Res. 2020;26(20):5400\u201310.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1176_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12920-021-01017-7","volume":"14","author":"JI Davila","year":"2021","unstructured":"Davila JI, Chanana P, Sarangi V, et al. Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Med Genomics. 2021;14(1):165.","journal-title":"BMC Med Genomics"},{"issue":"6706","key":"1176_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/23962","volume":"396","author":"T Kiyono","year":"1998","unstructured":"Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb\/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 1998;396(6706):84\u20138.","journal-title":"Nature"},{"issue":"5","key":"1176_CR28","doi-asserted-by":"publisher","first-page":"F1365","DOI":"10.1152\/ajprenal.90405.2008","volume":"295","author":"M Wieser","year":"2008","unstructured":"Wieser M, Stadler G, Jennings P, et al. hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol. 2008;295(5):F1365\u201375.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"1176_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/pros.23276","volume":"77","author":"MK Graham","year":"2017","unstructured":"Graham MK, Principessa L, Antony L, Meeker AK, Isaacs JT. Low p16INK4a expression in early passage human prostate basal epithelial cells enables immortalization by telomerase expression alone. Prostate. 2017;77(4):374\u201384.","journal-title":"Prostate"},{"issue":"10","key":"1176_CR30","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","volume":"96","author":"H Li","year":"2016","unstructured":"Li H, Chang LJ, Neubauer DR, Muir DF, Wallace MR. Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest. 2016;96(10):1105\u201315.","journal-title":"Lab Invest"},{"issue":"9","key":"1176_CR31","doi-asserted-by":"publisher","first-page":"e72162","DOI":"10.1371\/journal.pone.0072162","volume":"8","author":"MS Anglesio","year":"2013","unstructured":"Anglesio MS, Wiegand KC, Melnyk N, et al. Type-specific cell line models for type-specific ovarian cancer research. PLoS ONE. 2013;8(9):e72162.","journal-title":"PLoS ONE"},{"issue":"4","key":"1176_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/modpathol.2010.215","volume":"24","author":"SE Kalloger","year":"2011","unstructured":"Kalloger SE, K\u00f6bel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol. 2011;24(4):512\u201321.","journal-title":"Mod Pathol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01176-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T01:41:10Z","timestamp":1741311670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01176-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1176"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01176-0","relation":{},"ISSN":["1749-0774"],"issn-type":[{"type":"electronic","value":"1749-0774"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The use of fresh human ovarian cancer tissues was approved by the Research Ethics Committee of University of Fukui (reference number 20200176, approved on February 22, 2021). The analysis of human ovarian cancer tissues was approved by the Research Ethics Committee of University of Fukui (reference number 20200024, approved on May 19, 2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for the use of clinical specimens for medical research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"47"}}